AtriCure, Inc.
ATRC Healthcare Medical Instruments & Supplies
AtriCure, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $534.5 million, up 14.9% from fiscal 2024. In the quarter to June 2026, revenue grew 12.8%, EPS grew 238.5%, free cash flow fell 2.79% and total debt fell 4.43%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow ATRC
AtriCure, Inc. (ATRC) EV/Sales
As of 16 October 2026, AtriCure, Inc. (ATRC) trades at a EV/Sales of 4.7×. Over the past ten years it has ranged from 2.2× (June 2026) to 16.1× (June 2021); the current reading is higher than 52% of that period. That is above the Medical Instruments & Supplies industry median of 2.9× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.4× | 13.29% |
| FY2024 | 3.0× | (24.22%) |
| FY2023 | 4.0× | (34.68%) |
| FY2022 | 6.1× | (46.15%) |
| FY2021 | 11.2× | 7.21% |
| FY2020 | 10.5× | 99.51% |
| FY2019 | 5.3× | 9.44% |
| FY2018 | 4.8× | 39.21% |
| FY2017 | 3.5× | (11.15%) |
| FY2016 | 3.9× | (17.53%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.3× | (5.96%) |
| Mar 2026 | 2.4× | (29.34%) |
| Dec 2025 | 3.4× | 7.63% |
| Sep 2025 | 3.2× | 2.38% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| XRAY DENTSPLY SIRONA Inc. compare | 1.0× |
| NVST Envista Holdings Corporation compare | 1.4× |
| ICUI ICU Medical, Inc. compare | 2.3× |
| WRBY Warby Parker Inc. compare | 2.9× |
| STVN Stevanato Group S.p.A. compare | 3.9× |
| ATRC AtriCure, Inc. | 4.7× |
| LMAT LeMaitre Vascular, Inc. compare | 6.3× |
| KMTS Kestra Medical Technologies, Ltd. compare | 13.8× |
| PLSE Pulse Biosciences, Inc compare | 2,555× |
| Medical Instruments & Supplies industry median | 2.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)